EMEA-000371-PIP01-08 - paediatric investigation plan
lenalidomide
PIPHuman
Key facts
- Invented name
- Revlimid
- Revlimid
- Active Substance
- lenalidomide
- Therapeutic area
- Oncology
- Decision number
- P/102/2008
- PIP number
- EMEA-000371-PIP01-08
- Pharmaceutical form(s)
- Capsule, hard
- Condition(s) / indication(s)
- Myelodysplastic Syndrome
- Route(s) of administration
- Oral use
- Contact for public enquiries
Celgene Europe Limited
E-mail: medinfo.intl@celgene.com
Country: Switzerland
Phone: +41 327298500
Fax: +41 327298508- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date